Literature DB >> 21959954

Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways.

Mengying Yao1, Weihong Zhang, Qingxian Zhang, Lihua Xing, Aiguo Xu, Qiuhong Liu, Bing Cui.   

Abstract

BACKGROUND: Angiogenesis is an important process required for tumor progression. Mucin 1 (MUC1) is a transmembrane glycoprotein that is aberrantly upregulated in many types of cancer, including non-small-cell lung cancer (NSCLC). However, the biological significance of MUC1 overexpression in lung cancer angiogenesis is not completely understood.
METHODS: We showed that enforced expression of MUC1 in two NSCLC cell lines, A549 and NCI-H460, which have a low level of endogenous MUC1, promoted their ability to induce vascular endothelial growth factor (VEGF)-dependent endothelial cell migration and tube formation.
RESULTS: There was a significant increase in VEGF expression in MUC1-overexpressing NSCLC cells. Moreover, MUC1 overexpression resulted in a marked elevation in phosphorylated Akt and extracellular signal-regulated kinase (ERK)1/2, indicative of activation of both signaling pathways. Most importantly, inhibition of Akt or ERK signaling using specific chemical inhibitors restrained the proangiogenic activity of MUC1-overexpressing NSCLC cells.
CONCLUSIONS: Taken together, our present data demonstrate that the aberrant upregulation of MUC1 favors tumor angiogenesis in NSCLC, likely through the activation of both Akt and ERK pathways and elevation of VEGF production. MUC1 may thus be a potential antiangiogenic target in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21959954     DOI: 10.1007/s00408-011-9327-y

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  40 in total

1.  Cell-associated episialin is a complex containing two proteins derived from a common precursor.

Authors:  M J Ligtenberg; L Kruijshaar; F Buijs; M van Meijer; S V Litvinov; J Hilkens
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

Review 2.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

3.  Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer.

Authors:  I Papadopoulos; E Sivridis; A Giatromanolaki; M I Koukourakis
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

4.  Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003.

Authors:  Ping Yang; Mark S Allen; Marie C Aubry; Jason A Wampfler; Randolph S Marks; Eric S Edell; Stephen Thibodeau; Alex A Adjei; James Jett; Claude Deschamps
Journal:  Chest       Date:  2005-07       Impact factor: 9.410

5.  MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence.

Authors:  A Ohgami; T Tsuda; T Osaki; T Mitsudomi; Y Morimoto; T Higashi; K Yasumoto
Journal:  Ann Thorac Surg       Date:  1999-03       Impact factor: 4.330

6.  Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.

Authors:  Deepak Raina; Michio Kosugi; Rehan Ahmad; Govind Panchamoorthy; Hasan Rajabi; Maroof Alam; Takeshi Shimamura; Geoffrey I Shapiro; Jeffrey Supko; Surender Kharbanda; Donald Kufe
Journal:  Mol Cancer Ther       Date:  2011-03-18       Impact factor: 6.261

Review 7.  Anti-VEGF therapy in breast and lung mouse models of cancers.

Authors:  Marina Di Domenico; Carmela Ricciardi; Alfredo Fusco; Giovanna Maria Pierantoni
Journal:  J Biomed Biotechnol       Date:  2010-11-07

8.  Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells.

Authors:  Esther S Shao; Laura Lin; Yucheng Yao; Kristina I Boström
Journal:  Blood       Date:  2009-06-08       Impact factor: 22.113

9.  Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis.

Authors:  Andrew M Arsham; David R Plas; Craig B Thompson; M Celeste Simon
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

10.  Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer.

Authors:  N Khodarev; R Ahmad; H Rajabi; S Pitroda; T Kufe; C McClary; M D Joshi; D MacDermed; R Weichselbaum; D Kufe
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

View more
  15 in total

1.  Mucin-1 correlates with survival, smoking status, and growth patterns in lung adenocarcinoma.

Authors:  Elisa Lappi-Blanco; Johanna M Mäkinen; Siri Lehtonen; Henna Karvonen; Raija Sormunen; Kirsi Laitakari; Shirley Johnson; Riitta Mäkitaro; Risto Bloigu; Riitta Kaarteenaho
Journal:  Tumour Biol       Date:  2016-08-01

2.  Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.

Authors:  Akriti Kharbanda; Hasan Rajabi; Caining Jin; Jeremy Tchaicha; Eiki Kikuchi; Kwok-Kin Wong; Donald Kufe
Journal:  Clin Cancer Res       Date:  2014-09-04       Impact factor: 12.531

3.  β2-AR signaling controls trastuzumab resistance-dependent pathway.

Authors:  D Liu; Z Yang; T Wang; Z Yang; H Chen; Y Hu; C Hu; L Guo; Q Deng; Y Liu; M Yu; M Shi; N Du; N Guo
Journal:  Oncogene       Date:  2015-03-23       Impact factor: 9.867

Review 4.  Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer.

Authors:  Jos P M van Putten; Karin Strijbis
Journal:  J Innate Immun       Date:  2017-01-05       Impact factor: 7.349

5.  MUC1-C oncoprotein activates ERK→C/EBPβ signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells.

Authors:  Maroof Alam; Rehan Ahmad; Hasan Rajabi; Akriti Kharbanda; Donald Kufe
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

Review 6.  Targeted immunotherapy for non-small cell lung cancer.

Authors:  Monali Vasekar; Xin Liu; Hong Zheng; Chandra P Belani
Journal:  World J Clin Oncol       Date:  2014-05-10

Review 7.  MUC1 and metastatic cancer: expression, function and therapeutic targeting.

Authors:  Teresa M Horm; Joyce A Schroeder
Journal:  Cell Adh Migr       Date:  2013-01-09       Impact factor: 3.405

Review 8.  MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.

Authors:  D W Kufe
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

9.  Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A.

Authors:  Hongxia Chen; Lingmin Li; Shaojun Wang; Yupeng Lei; Qi Ge; Nonghua Lv; Xiaodong Zhou; Changyan Chen
Journal:  Oncotarget       Date:  2014-12-15

10.  MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.

Authors:  Masayuki Hiraki; Yozo Suzuki; Maroof Alam; Kunihiko Hinohara; Masanori Hasegawa; Caining Jin; Surender Kharbanda; Donald Kufe
Journal:  Sci Rep       Date:  2016-05-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.